Noriyo Yamashiki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6833034/publications.pdf

Version: 2024-02-01

279487 253896 2,246 76 23 43 citations h-index g-index papers 76 76 76 3011 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis. Abdominal Radiology, 2021, 46, 3790-3797.	1.0	11
2	A giant Brunner gland hamartoma successfully treated by endoscopic excision followed by transanal retrieval. Medicine (United States), 2021, 100, e25048.	0.4	3
3	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	1.8	62
4	Use of Nakanuma staging and cytokeratinÂ7 staining for diagnosing recurrent primary biliary cholangitis after livingâ€donor liver transplantation. Hepatology Research, 2020, 50, 478-487.	1.8	5
5	A case of noncirrhotic hepatic encephalopathy due to porto-hepatic venous shunt successfully treated with percutaneous transhepatic obliteration. Acta Hepatologica Japonica, 2020, 61, 582-587.	0.0	0
6	Alcohol relapse and its predictors after liver transplantation for alcoholic liver disease: a systematic review and meta-analysis. BMC Gastroenterology, 2019, 19, 150.	0.8	54
7	Mediumâ€chain triglycerides supplement therapy with a lowâ€carbohydrate formula can supply energy and enhance ammonia detoxification in the hepatocytes of patients with adult–onset type II citrullinemia. Journal of Inherited Metabolic Disease, 2018, 41, 777-784.	1.7	27
8	Impact of Donor Age on Recipient Survival in Adult-to-Adult Living-donor Liver Transplantation. Annals of Surgery, 2018, 267, 1126-1133.	2.1	63
9	Coexistence of Bilirubin ≥10 mg/dL and Prothrombin Time-International Normalized Ratio ≥1.6 on Day 7. Transplantation, 2018, 102, 440-447.	0.5	15
10	Development of a Mobile Application for Living Liver Donors to Assist their Understandings of a Series of Preoperative Tests. Transplantation, 2018, 102, S248.	0.5	0
11	The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of antiâ€∢scp>HBc–positive livers. Pediatric Transplantation, 2018, 22, e13227.	0.5	9
12	NELFCD and CTSZ loci are associated with jaundice-stage progression in primary biliary cholangitis in the Japanese population. Scientific Reports, 2018, 8, 8071.	1.6	8
13	Clinical Outcomes after Liver Transplantation for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. BioMed Research International, 2018, 2018, 1-8.	0.9	19
14	Clinical Outcomes after Liver Transplantation for Hepatorenal Syndrome: A Systematic Review and Metaanalysis. Gastroenterology, 2017, 152, S1123.	0.6	3
15	The role of hepatologists in liver transplantation; the results of questionnaire survey for institutions belonging to the Japanese Liver Transplantation Society. Acta Hepatologica Japonica, 2017, 58, 97-104.	0.0	0
16	Long-term Prognosis and Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A Single-Center Experience. Transplantation Direct, 2017, 3, e334.	0.8	30
17	Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatology Research, 2016, 46, 541-551.	1.8	12
18	Chronologic changes of explanted liver volume and the use of ursodeoxycholic acid in patients with endâ€stage primary biliary cirrhosis. Hepatology Research, 2014, 44, 993-999.	1.8	1

#	Article	IF	Citations
19	Living donor liver transplantation for nonâ€alcoholic steatohepatitis: A single center experience. Hepatology Research, 2014, 44, E3-E10.	1.8	18
20	Impact of Donor and Recipient Single Nucleotide Polymorphisms of IL28B rs8099917 in Living Donor Liver Transplantation for Hepatitis C. PLoS ONE, 2014, 9, e90462.	1.1	4
21	Newâ€onset diabetes mellitus developing in Asian adult living donor liver transplant recipients: a singleâ€center experience. Journal of Hepato-Biliary-Pancreatic Sciences, 2013, 20, 634-638.	1.4	9
22	Living donor liver transplantation for patients immunized against human leukocyte antigen. Journal of Hepato-Biliary-Pancreatic Sciences, 2013, 20, 279-285.	1.4	5
23	Quality of life after adult living donor liver transplantation: A longitudinal prospective followâ€up study. Hepatology Research, 2013, 43, 1052-1063.	1.8	16
24	Role of 6â€month abstinence rule in living donor liver transplantation for patients with alcoholic liver disease. Hepatology Research, 2013, 43, 1169-1174.	1.8	17
25	CT With Hepatic Arterioportography as a Pretreatment Examination for Hepatocellular Carcinoma Patients: A Randomized Controlled Trial. American Journal of Gastroenterology, 2013, 108, 1305-1313.	0.2	8
26	De Novo Malignancies After Adult-to-Adult Living-Donor Liver Transplantation With a Malignancy Surveillance Program. Transplantation, 2013, 95, 1142-1147.	0.5	28
27	Changes in Risk of Immediate Adverse Reactions to Iodinated Contrast Media by Repeated Administrations in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e76018.	1.1	15
28	Cooperation with community-based hospital and liver transplant program: a regional questionnaire-based survey on referring indications. Acta Hepatologica Japonica, 2013, 54, 211-213.	0.0	0
29	Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. Journal of Gastroenterology, 2012, 47, 1152-1159.	2.3	11
30	Lower Incidence of Biliary Carcinoma in Patients With Primary Sclerosing Cholangitis and High Serum Levels of Immunoglobulin E. Clinical Gastroenterology and Hepatology, 2012, 10, 79-83.	2.4	13
31	Outcomes after living donor liver transplantation for acute liver failure in Japan: Results of a nationwide survey. Liver Transplantation, 2012, 18, 1069-1077.	1.3	67
32	Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population. American Journal of Human Genetics, 2012, 91, 721-728.	2.6	251
33	Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial. Hepatology International, 2012, 6, 639-645.	1.9	5
34	Living donor liver transplantation using sensitized lymphocytotoxic crossmatch positive graft. Journal of Gastroenterology, 2012, 47, 486-488.	2.3	9
35	Long-term outcome of living donor liver transplantation for primary biliary cirrhosis. Transplant International, 2012, 25, 7-12.	0.8	15
36	Thrombotic Microangiopathy After Living-Donor Liver Transplantation. American Journal of Transplantation, 2012, 12, 728-736.	2.6	23

3

#	Article	IF	CITATIONS
37	Livingâ€donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis–primary biliary cirrhosis overlap syndrome. Hepatology Research, 2012, 42, 1016-1023.	1.8	12
38	Preemptive Antiviral Treatment for Hepatitis C Virus After Living Donor Liver Transplantation. Transplantation Proceedings, 2012, 44, 791-793.	0.3	9
39	Model for End-stage Liver Disease and Model for End-stage Liver Disease-Na Scores Predict Both Before-Listing and Wait-List Mortality. Transplantation Proceedings, 2012, 44, 389-392.	0.3	9
40	Diagnostic accuracy of αâ€fetoprotein and desâ€Î³â€carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates. Hepatology Research, 2011, 41, 1199-1207.	1.8	12
41	Once-daily tacrolimus in living donor liver transplant recipients. BioScience Trends, 2011, 5, 156-158.	1.1	3
42	Outcome of Liver Transplantation for Recipients With Hepatitis B and Hepatitis C Virus Coinfection: Analysis of the UNOS Data. Transplantation, 2011, 92, 809-814.	0.5	13
43	Donor quality of life after living donor liver transplantation: a prospective study. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 263-267.	1.4	24
44	Discrepancy between estimated and actual weight of partial liver graft from living donors. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 586-591.	1.4	19
45	Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis. BioScience Trends, 2011, 5, 57-60.	1.1	6
46	Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transplant International, 2010, 23, 580-588.	0.8	21
47	Postoperative surveillance with monthly serum tumor markers after livingâ€donor liver transplantation for hepatocellular carcinoma. Hepatology Research, 2010, 40, 278-286.	1.8	19
48	The urgent need for evaluating recurrent primary sclerosing cholangitis in living donor liver transplantation. Liver Transplantation, 2009, 15, 1383-1384.	1.3	4
49	Assessment of liver stiffness in patients after living donor liver transplantation by transient elastography. Scandinavian Journal of Gastroenterology, 2009, 44, 1115-1120.	0.6	19
50	Doubleâ€dose doubleâ€phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients. Hepatology Research, 2009, 39, 7-13.	1.8	12
51	Noninvasive Estimation of Hepatic Steatosis in Living Liver Donors: Usefulness of Visceral Fat Area Measurement. Transplantation, 2009, 88, 575-581.	0.5	18
52	Referral, evaluation, and listing for deceased donor liver transplantation in Japan: University of Tokyo experience. Acta Hepatologica Japonica, 2009, 50, 634-643.	0.0	0
53	Outcome of living donor liver transplantation for post-Kasai biliary atresia in adults. Liver Transplantation, 2008, 14, 186-192.	1.3	24
54	Living donor liver transplantation for fulminant hepatic failure. Hepatology Research, 2008, 38, 987-996.	1.8	24

#	Article	IF	CITATIONS
55	Obesity Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. Clinical Gastroenterology and Hepatology, 2008, 6, 459-464.	2.4	149
56	Recurrence of cholestatic liver disease after living donor liver transplantation. World Journal of Gastroenterology, 2008, 14, 5105.	1.4	9
57	The role and perspective of transplant hepatologists in Japan. Acta Hepatologica Japonica, 2008, 49, 28-38.	0.0	3
58	Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 197-203.	1.4	54
59	Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 2155-2160.	1.4	14
60	Systematic grading of surgical complications in live liver donors according to Clavien's system. Transplant International, 2006, 19, 982-987.	0.8	56
61	Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology, 2006, 44, 1518-1527.	3.6	132
62	Selection of liver-transplant candidates for adult-to-adult living donor liver transplantation as the only surgical option for end-stage liver disease. Liver Transplantation, 2006, 12, 1077-1083.	1.3	34
63	Ablation therapy in containing extension of hepatocellular carcinoma: A simulative analysis of dropout from the waiting list for liver transplantation. Liver Transplantation, 2005, 11, 508-514.	1.3	20
64	Competing Risks Analysis of Predictors of Delisting Owing to Tumor Progression in Liver Transplant Candidates with Hepatocellular Carcinoma. American Journal of Transplantation, 2004, 4, 774-781.	2.6	29
65	Histopathological changes after microwave coagulation therapy for patients with hepatocellular carcinoma: review of 15 explanted livers. American Journal of Gastroenterology, 2003, 98, 2052-2059.	0.2	40
66	The role of intestinal transplantation in the management of babies with extensive gut resections. Journal of Pediatric Surgery, 2003, 38, 145-149.	0.8	41
67	Comparison of hepatic resection and hepatic transplantation in the treatment of hepatocellular carcinoma among cirrhotic patients. Annals of Surgical Oncology, 2002, 9, 881-886.	0.7	34
68	Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. European Journal of Gastroenterology and Hepatology, 2001, 13, 291-294.	0.8	80
69	Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer, 2000, 89, 1245-1251.	2.0	137
70	Regulatory mechanisms for transforming growth factorl ² as an autocrine inhibitor in human hepatocellular carcinoma: Implications for roles of Smads in its growth. Hepatology, 2000, 32, 218-227.	3.6	46
71	Effects of Alcohol Consumption on Histological Changes in Chronic Hepatitis C: A Clinicopathological Study. Alcoholism: Clinical and Experimental Research, 2000, 24, 106S.	1.4	13
72	Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer, 2000, 89, 1245-1251.	2.0	2

#	Article	IF	CITATION
73	Percutaneous Microwave Coagulation Therapy for Solitary Metastatic Liver Tumors From Colorectal Cancer: A Pilot Clinical Study. American Journal of Gastroenterology, 1999, 94, 322-327.	0.2	65
74	Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma. , 1999, 85, $1694-1702$.		175
75	Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma. Cancer, 1999, 85, 1694-1702.	2.0	12
76	Hepatic infarction following percutaneous ethanol injection therapy for hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 1998, 10, 915-918.	0.8	17